Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Catabasis Pharma (CATB)

Catabasis Pharma (CATB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,337
  • Shares Outstanding, K 3,904
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,300 K
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.00
Trade CATB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.84
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 08/09/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.81
  • Number of Estimates 3
  • High Estimate -0.64
  • Low Estimate -1.14
  • Prior Year -3.36
  • Growth Rate Est. (year over year) +75.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.31 +35.34%
on 08/20/21
10.26 -16.76%
on 09/02/21
-0.76 (-8.17%)
since 08/06/21
3-Month
6.31 +35.34%
on 08/20/21
15.72 -45.67%
on 06/16/21
-4.42 (-34.10%)
since 06/08/21
52-Week
6.31 +35.34%
on 08/20/21
47.82 -82.14%
on 01/29/21
-30.58 (-78.17%)
since 09/08/20

Most Recent Stories

More News
Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc....

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

CATB : 8.54 (-6.97%)
Xontogeny Announces Launch of Several New Early-Stage Portfolio Companies

Xontogeny LLC , a Boston-based accelerator that provides seed-stage investments along with strategic and operational support to early-stage life science companies, unveiled five of its latest portfolio...

LABP : 6.64 (unch)
CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update....

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide information...

CATB : 8.54 (-6.97%)
Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company...

CATB : 8.54 (-6.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054...

See More

Key Turning Points

3rd Resistance Point 9.76
2nd Resistance Point 9.49
1st Resistance Point 9.01
Last Price 8.54
1st Support Level 8.26
2nd Support Level 7.99
3rd Support Level 7.51

See More

52-Week High 47.82
Fibonacci 61.8% 31.96
Fibonacci 50% 27.07
Fibonacci 38.2% 22.17
Last Price 8.54
52-Week Low 6.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar